Latest Commercialisation News

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Conrad Asia Energy reports solid progress in Q4 2024 with finalized gas sales agreements and promising LNG studies, despite delayed final investment decisions due to regulatory approvals.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.

IPB Petroleum has appointed a new chairman and is intensifying efforts to secure funding for drilling its key Browse Basin assets, while maintaining a strong cash position and exploring new project opportunities.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

Australian Rare Earths Limited has secured a $5 million government grant to advance its Koppamurra Rare Earths Project, while initial drilling at its Overland Uranium Project validates promising geological models for uranium deposits.

Godolphin Resources reports significant drilling success at Lewis Ponds with thick massive sulphide intersections and advances its Narraburra Rare Earths project with high-value carbonate samples, supported by a strong capital raise.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Condor Energy Ltd has raised A$3 million through a well-supported placement to advance its exploration and commercialisation efforts in the Tumbes Basin offshore Peru, focusing on the promising Piedra Redonda gas discovery.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

Vulcan Energy has successfully closed its Share Purchase Plan, raising approximately A$8 million through the issuance of over 1.3 million new shares, following a major institutional placement. This capital injection supports the company’s pioneering lithium and renewable energy projects in Europe.